Breast Cancer clinical trials in South Dakota

9 actively recruiting breast cancer trials at 3 sites across South Dakota.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05929768

Sites in South Dakota:

Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT06876714

Sites in South Dakota:

Rapid City Regional Hospital — Rapid City, South Dakota
Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

E-Mindfulness Approaches for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …

Sponsor: NRG Oncology

NCT ID: NCT06748222

Sites in South Dakota:

Rapid City Regional Hospital — Rapid City, South Dakota

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…

Sponsor: AstraZeneca

NCT ID: NCT05952557

Sites in South Dakota:

Research Site — Aberdeen, South Dakota
Research Site — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…

Sponsor: Novartis Pharmaceuticals

NCT ID: NCT05827081

Sites in South Dakota:

Sanford USD Medical Center — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…

Sponsor: Hoffmann-La Roche

NCT ID: NCT06065748

Sites in South Dakota:

Avera Cancer Institute - Aberdeen — Aberdeen, South Dakota
Avera Cancer Institute — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05564377

Sites in South Dakota:

Rapid City Regional Hospital — Rapid City, South Dakota
Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

NA Recruiting Network

Mobile Health for Adherence in Breast Cancer Patients

This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to e…

Sponsor: ECOG-ACRIN Cancer Research Group

NCT ID: NCT06112613

Sites in South Dakota:

Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at ag…

Sponsor: University of California, San Francisco

NCT ID: NCT02620852

Sites in South Dakota:

Edith Sanford Breast Center — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20